LOS ANGELES (KABC) -- The Food and Drug Administration's approval process is one of the most stringent in the world, but now some experts are questioning newer drugs that go through a quicker review.

The U.S. Food and Drug Administration (FDA) announced a new process called “Rare Disease Evidence Principles” (RDEP), under which eligible drugs and biologics for ultra-rare diseases caused by known ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

A stronger 7.2 mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include novel drugs that offer new treatment options, as well as first generics and ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

Food and Drug Administration Commissioner Marty Makary said approving drugs for human consumption is moving at a “record” pace. Makary confirmed that the FDA’s review process will not slow down ...

Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease ...